Search
Namilumab
go.drugbank.com/drugs/DB13037InvestigationalNamilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.
MG98
go.drugbank.com/drugs/DB06544ExperimentalMG98, a second-generation antisense oligodeoxynucleotide inhibitor of human DNMT1, was investigated in the completed clinical trial NCT00003890 for treating patients with advanced solid tumors.
Gonadorelin
go.drugbank.com/drugs/DB00644ApprovedInvestigationalVet approvedGonadorelin is another name for gonadotropin-releasing hormone (GnRH). It is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormon...
Afimoxifene
go.drugbank.com/drugs/DB04468InvestigationalAfimoxifene (4-Hydroxytamoxifen, trade name TamoGel) is a new estrogen inhibitor under investigation for a variety of estrogen-dependent conditions, including cyclic breast pain and gynecomastia. TamoGel is formulated using Enhanced Hydr...
Noxytiolin
go.drugbank.com/drugs/DB13838ApprovedLocal antibacterial that probably acts by releasing formaldehyde in aqueous solutions.
Praliciguat
go.drugbank.com/drugs/DB16300InvestigationalPraliciguat is under investigation in clinical trial NCT03254485 (A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (Hfpef)).
KITE-585
go.drugbank.com/drugs/DB17409InvestigationalKITE-585 is an autologous, fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy. It is being investigated in the treatment of multiple myeloma.
AZD8630
go.drugbank.com/drugs/DB19397InvestigationalAZD8630 is an experimental drug under investigation, as described in the Phase I clinical study titled "Randomised, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics
Reglitazar
go.drugbank.com/drugs/DB04971ExperimentalReglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.